
Dr. Raje on the Design of the ENDURANCE Trial in Newly Diagnosed Multiple Myeloma
Noopur S. Raje, MD, discusses the design of the randomized phase 3 ENDURANCE trial in newly diagnosed multiple myeloma.
Noopur S. Raje, MD, professor of medicine at Harvard Medical School and director of the Multiple Myeloma Program at Massachusetts General Hospital, discusses the design of the randomized phase 3 ENDURANCE (E1A11) trial in newly diagnosed multiple myeloma.
At the
The trial randomized patients to receive KRd (n = 545) versus VRd (n = 542), says Raje. Notably, these are 2 of the most commonly used induction regimens in this space, Raje concludes.



































